Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Accured Expenses: 2018-2025

Historic Change in Accured Expenses for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $985,000.

  • Whitehawk Therapeutics' Change in Accured Expenses rose 116.15% to $985,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$156,000, marking a year-over-year increase of 97.19%. This contributed to the annual value of -$9.8 million for FY2024, which is 7303.79% down from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Change in Accured Expenses stood at $985,000, which was up 136.37% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Change in Accured Expenses registered a high of $5.0 million during Q3 2022, and its lowest value of -$9.8 million during Q3 2021.
  • Over the past 3 years, Whitehawk Therapeutics' median Change in Accured Expenses value was $592,000 (recorded in 2024), while the average stood at -$968,455.
  • The largest annual percentage gain for Whitehawk Therapeutics' Change in Accured Expenses in the last 5 years was 740.65% (2022), contrasted with its biggest fall of 797.47% (2022).
  • Whitehawk Therapeutics' Change in Accured Expenses (Quarterly) stood at $155,000 in 2021, then skyrocketed by 740.65% to $1.3 million in 2022, then surged by 269.53% to $4.8 million in 2023, then slumped by 87.71% to $592,000 in 2024, then skyrocketed by 116.15% to $985,000 in 2025.
  • Its Change in Accured Expenses stands at $985,000 for Q3 2025, versus -$2.7 million for Q2 2025 and $975,000 for Q1 2025.